Skip to content
TrialScanner

NCT05184764

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Phase 1/Phase 2CompletedARMPLead

Registry record

Lead sponsor
Armata Pharmaceuticals, Inc.
Conditions
Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Due to Staphylococcus Aureus
Primary completion
Nov 7, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05184764 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05184764: Study Evaluating Safety... | TrialScanner